Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jan;313(1):358-375.
doi: 10.1111/imr.13138. Epub 2022 Sep 25.

With complements: C3 inhibition in the clinic

Martin Kolev  1 , Tara Barbour  1 , Scott Baver  1 , Cedric Francois  1 , Pascal Deschatelets  1
Affiliations
Review

With complements: C3 inhibition in the clinic

Martin Kolev et al. Immunol Rev. 2023 Jan.

Abstract

C3 is a key complement protein, located at the nexus of all complement activation pathways. Extracellular, tissue, cell-derived, and intracellular C3 plays critical roles in the immune response that is dysregulated in many diseases, making it an attractive therapeutic target. However, challenges such as very high concentration in blood, increased acute expression, and the elevated risk of infections have historically posed significant challenges in the development of C3-targeted therapeutics. This is further complicated because C3 activation fragments and their receptors trigger a complex network of downstream effects; therefore, a clear understanding of these is needed to provide context for a better understanding of the mechanism of action (MoA) of C3 inhibitors, such as pegcetacoplan. Because of C3's differential upstream position to C5 in the complement cascade, there are mechanistic differences between pegcetacoplan and eculizumab that determine their efficacy in patients with paroxysmal nocturnal hemoglobinuria. In this review, we compare the MoA of pegcetacoplan and eculizumab in paroxysmal nocturnal hemoglobinuria and discuss the complement-mediated disease that might be amenable to C3 inhibition. We further discuss the current state and outlook for C3-targeted therapeutics and provide our perspective on which diseases might be the next success stories in the C3 therapeutics journey.

Keywords: C3; C3-targeted therapeutics; complement system; complement-mediated disease; compstatin; pegcetacoplan.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

REFERENCES

    1. Kerboua KE, Djenouhat K. Complementology's foundation: the 100-year anniversary of the Nobel Prize to Jules Bordet. J Immunoassay Immunochem. 2019;41(1):106-116. doi:10.1080/15321819.2019.1689999
    1. Nonaka M. Evolution of the complement system. Subcell Biochem. 2014;80:31-43. doi:10.1007/978-94-017-8881-6_3
    1. Kolev M, Kemper C. Keeping it all going-complement meets metabolism. Front Immunol. 2017;8:1. doi:10.3389/FIMMU.2017.00001
    1. Kolev M, Dimeloe S, Le Friec G, et al. Complement regulates nutrient influx and metabolic reprogramming during Th1 cell responses. Immunity. 2015;42(6):1033-1047. doi:10.1016/J.IMMUNI.2015.05.024
    1. Liszewski MK, Kolev M, Le Friec G, et al. Intracellular complement activation sustains T cell homeostasis and mediates effector differentiation. Immunity. 2013;39(6):1143-1157. doi:10.1016/J.IMMUNI.2013.10.018

MeSH terms

LinkOut - more resources